Literature DB >> 21430300

Genetic polymorphisms in inflammation pathway genes and prostate cancer risk.

Erika M Kwon1, Claudia A Salinas, Suzanne Kolb, Rong Fu, Ziding Feng, Janet L Stanford, Elaine A Ostrander.   

Abstract

BACKGROUND: Chronic inflammation is an important mechanism for the development and progression of prostate cancer (PC). To better understand the potential relationship between genes in the inflammation pathway and PC risk, we evaluated variants in 16 candidate genes.
METHODS: A total of 143 tagging and amino acid altering single nucleotide polymorphisms (SNPs) were genotyped in Caucasian and African American men participating in one of two population-based, case-control studies (n = 1,458 cases and 1,351 controls). The relative risk of PC was estimated using logistic and polytomous regression models.
RESULTS: Ten SNPs in seven genes (CXCL12, IL4, IL6, IL6ST, PTGS2, STAT3, and TNF) were nominally associated (P < 0.05) with risk of PC in Caucasians. The most significant effect on risk was seen with rs11574783 in the interleukin 6 signal transducer (IL6ST) gene (OR = 0.08, 95% CI: 0.01-0.63). Cumulatively, four SNPs in genes interleukin 4 (IL4), IL6ST, PTGS2, and signal transducer and activator of transcription 3 (STAT3) conferred a three-fold elevation in PC risk among men carrying the maximum number of high-risk alleles (OR = 2.97, 95% CI: 1.41-6.25, P(trend) = 0.0003). Risk estimates for seven SNPs varied significantly according to disease aggressiveness (P(homogeneity) < 0.05), with SNPs in AKT1, PIK3R1, and STAT3 independently associated with more aggressive PC; OR = 5.1 (95% CI: 2.29-11.40, P(trend) = 3.8 × 10(-5)) for carriers of all high-risk genotypes.
CONCLUSIONS: These results suggest that variants in genes within the inflammation pathway may play a role in the development of PC, however, further studies are needed to replicate our findings. IMPACT: These results underline the potential importance of the inflammation pathway in PC development and progression. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21430300      PMCID: PMC3140053          DOI: 10.1158/1055-9965.EPI-10-0994

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  44 in total

1.  Marker selection by Akaike information criterion and Bayesian information criterion.

Authors:  W Li; D R Nyholt
Journal:  Genet Epidemiol       Date:  2001       Impact factor: 2.135

Review 2.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

3.  Vasectomy and risk of prostate cancer.

Authors:  J L Stanford; K G Wicklund; B McKnight; J R Daling; M K Brawer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1999-10       Impact factor: 4.254

4.  Cytokine variations in patients with hormone treated prostate cancer.

Authors:  G J Wise; V K Marella; G Talluri; D Shirazian
Journal:  J Urol       Date:  2000-09       Impact factor: 7.450

5.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

6.  Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia.

Authors:  L M Lee; C C Pan; C J Cheng; C W Chi; T Y Liu
Journal:  Anticancer Res       Date:  2001 Mar-Apr       Impact factor: 2.480

Review 7.  Inflammation and cancer: back to Virchow?

Authors:  F Balkwill; A Mantovani
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

8.  Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment.

Authors:  S Madaan; P D Abel; K S Chaudhary; R Hewitt; M A Stott; G W Stamp; E N Lalani
Journal:  BJU Int       Date:  2000-10       Impact factor: 5.588

9.  Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells.

Authors:  V Subbarayan; A L Sabichi; N Llansa; S M Lippman; D G Menter
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

10.  Influence of cytokine gene polymorphisms on the development of prostate cancer.

Authors:  Sarah L McCarron; Stephen Edwards; Philip R Evans; Roz Gibbs; David P Dearnaley; Anna Dowe; Christine Southgate; Douglas F Easton; Rosalind A Eeles; W Martin Howell
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

View more
  26 in total

Review 1.  Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments.

Authors:  C R Balistreri; G Candore; D Lio; G Carruba
Journal:  Cancer Gene Ther       Date:  2014-01-10       Impact factor: 5.987

2.  CXCL12 G801A polymorphism and cancer risk: An updated meta-analysis.

Authors:  Dan Meng; Yin-Xiang Wu; Vidhi Heerah; Shuang Peng; Meng-di Chu; Yong-Jian Xu; Wei-Ning Xiong; Shu-Yun Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-06-14

3.  Association between STAT3 polymorphisms and cancer risk: a meta-analysis.

Authors:  Ruicheng Yan; Fusheng Lin; Chao Hu; Shilun Tong
Journal:  Mol Genet Genomics       Date:  2015-06-11       Impact factor: 3.291

Review 4.  Prostate cancer and inflammation: the evidence.

Authors:  Karen S Sfanos; Angelo M De Marzo
Journal:  Histopathology       Date:  2012-01       Impact factor: 5.087

5.  Associations of immunity-related single nucleotide polymorphisms with overall survival among prostate cancer patients.

Authors:  Fayth L Miles; Jian-Yu Rao; Curtis Eckhert; Shen-Chih Chang; Allan Pantuck; Zuo-Feng Zhang
Journal:  Int J Clin Exp Med       Date:  2015-06-24

6.  Impact of prostate inflammation on lesion development in the POET3(+)Pten(+/-) mouse model of prostate carcinogenesis.

Authors:  Grant N Burcham; Gregory M Cresswell; Paul W Snyder; Long Chen; Xiaoqi Liu; Scott A Crist; Michael D Henry; Timothy L Ratliff
Journal:  Am J Pathol       Date:  2014-11-22       Impact factor: 4.307

7.  Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort.

Authors:  Qinchuan Wang; Justin R Gregg; Jian Gu; Yuanqing Ye; David W Chang; John W Davis; Timothy C Thompson; Jeri Kim; Christopher J Logothetis; Xifeng Wu
Journal:  Oncoimmunology       Date:  2018-10-29       Impact factor: 8.110

8.  Genome-wide germline correlates of the epigenetic landscape of prostate cancer.

Authors:  Kathleen E Houlahan; Yu-Jia Shiah; Alexander Gusev; Jiapei Yuan; Musaddeque Ahmed; Anamay Shetty; Susmita G Ramanand; Cindy Q Yao; Connor Bell; Edward O'Connor; Vincent Huang; Michael Fraser; Lawrence E Heisler; Julie Livingstone; Takafumi N Yamaguchi; Alexandre Rouette; Adrien Foucal; Shadrielle Melijah G Espiritu; Ankit Sinha; Michelle Sam; Lee Timms; Jeremy Johns; Ada Wong; Alex Murison; Michèle Orain; Valérie Picard; Hélène Hovington; Alain Bergeron; Louis Lacombe; Mathieu Lupien; Yves Fradet; Bernard Têtu; John D McPherson; Bogdan Pasaniuc; Thomas Kislinger; Melvin L K Chua; Mark M Pomerantz; Theodorus van der Kwast; Matthew L Freedman; Ram S Mani; Housheng H He; Robert G Bristow; Paul C Boutros
Journal:  Nat Med       Date:  2019-10-07       Impact factor: 53.440

9.  Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk.

Authors:  Erika M Kwon; Sarah K Holt; Rong Fu; Suzanne Kolb; Gabrielle Williams; Janet L Stanford; Elaine A Ostrander
Journal:  Cancer Epidemiol       Date:  2012-04-26       Impact factor: 2.984

10.  Polymorphisms of the Interleukin 6 gene contribute to cervical cancer susceptibility in Eastern Chinese women.

Authors:  Ting-Yan Shi; Mei-Ling Zhu; Jing He; Meng-Yun Wang; Qiao-Xin Li; Xiao-Yan Zhou; Meng-Hong Sun; Zhi-Ming Shao; Ke-Da Yu; Xi Cheng; Xiaohua Wu; Qingyi Wei
Journal:  Hum Genet       Date:  2012-11-20       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.